copy of dr. west on fda approval of frontline osimertinib in egfr nsclc
Published 6 years ago • 38 plays • Length 0:40Download video MP4
Download video MP3
Similar videos
-
3:14
dr. west on fda approval of frontline osimertinib in egfr nsclc
-
1:21
fda approval of frontline osimertinib in frontline egfr-mutant nsclc
-
1:47
dr. west on fda approval of afatinib in nsclc with rare egfr mutations
-
0:55
dr. west on fda approval of frontline alectinib in alk nsclc
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
0:59
dr. west on emerging changes in the field of egfr-mutant nsclc
-
1:21
dr. kris on the fda approval of dacomitinib in egfr nsclc
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
1:54
dr. wakelee on fda approval of frontline pembrolizumab in nsclc
-
6:51
osimertinib as frontline therapy in egfr-positive nsclc
-
8:11
advances in frontline therapy for egfr nsclc
-
1:02
osimertinib for treatment of egfr lung cancer
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
1:36
comment: front-line osimertinib significantly lengthens overall survival in egfr-mutation positi...
-
7:45
upfront use of osimertinib in egfr nsclc
-
5:18
frontline therapy for egfr plus nsclc: osimertinib’s impact
-
1:45
dr. ramalingam on the use of osimertinib in clinical trial and real-world settings
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
2:00
dr. goldberg on sequencing following treatment with osimertinib in nsclc